在心力衰竭中双边动脉重血管化
Finny Quilty1, Alexandra Alice Irene Abel2, Andrew Lawrence Clark1
1Department of Cardiorespiratory Medicine, Hull York Medical School, Hull, UK.
BMJ case reports
|April 25, 2024
概括
双边动脉复血管化使心力衰竭患者能够安全使用ACE抑制剂. 这种干预有助于优化静心功能障碍的医疗治疗,改善心力衰竭的管理.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 血管医学 血管医学
背景情况:
- 减少喷射分数 (HFrEF) 的心力衰竭管理因动脉狭窄症 (RAS) 而复杂.
- RAS是血管激素转化酶 (ACE) 抑制剂的禁用,这是HFrEF的基石治疗.
- 在患有并发RAS.AS的患者中,HFrEF的最佳药物治疗往往是无法实现的.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370


